We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.75 | 2.75% | 28.00 | 27.60 | 28.00 | 27.80 | 27.25 | 27.25 | 2,093,935 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.73 | 185.4M |
From Jul 2019 to Jul 2024
TIDMVENN
RNS Number : 3854D
Venn Life Sciences Holdings PLC
28 January 2015
28 January 2015
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Grant of Share Options
& Total Voting Rights
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that it has today granted options over 2,870,000 ordinary shares representing to 10.12% of the current issued share capital.
Included in these options are options over 1,680,000 ordinary shares that have been granted to certain Directors (the "Director Options"), details of which are below:
Hot Features
Premium
Director No. of ordinary Percentage of Exercise Exercise period
shares under issued share price
option capital represented
by the options
From 28 January
2018 until 27
Tony Richardson 910,000 3.21% 25p January 2025
From 28 January
2018 until 27
Gracielle Beijerbacht-Schutjens 770,000 2.72% 25p January 2025
The Director Options vest when the share price reaches 40p per share.
The remaining options over 1,190,000 ordinary shares are being granted to a number of Venn Life Sciences employees. They are intended to reward commitment and loyalty, will be exercisable between the third and tenth anniversary of grant and have no performance criteria.
Following this grant the Company has granted options over 2,870,000 ordinary shares and has no intention to further increase the percentage of its issued share capital under option.
Total Voting Rights Correction
This announcement also corrects the figure for Total Voting Rights which was previously contained in an announcement on 8 September 2014. The Company's issued share capital consists of 28,359,221 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that the total number of voting rights in the Company are 28,359,221.
Venn Life Sciences Holdings Plc www.vennlifesciences.com Tony Richardson, Chief Executive Tel: +353 154 99 341 Officer Orla Mc Guinness, Marketing Manager Tel: +353 153 73 269 Zeus Capital (Nominated Adviser and Broker) Ross Andrews/ Andrew Jones Tel: +44 (0)161 831 1512 Dominic Wilson Tel: +44 (0)20 7533 7727 Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893 Lianne Cawthorne Mob: +44 (0)7584 391 303
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSLLFIFLVITFIE
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
